Profile data is unavailable for this security.
About the company
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
- Revenue in JPY (TTM)66.16bn
- Net income in JPY5.90bn
- Incorporated1955
- Employees1.74k
- LocationZeria Pharmaceutical Co Ltd10-11, Nihombashi Kobuna-choCHUO-KU 103-8351JapanJPN
- Phone+81 336632351
- Fax+81 336632352
- Websitehttp://www.zeria.co.jp
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNI Group Ltd | 15.91bn | 847.96m | 58.27bn | 629.00 | 69.48 | 2.54 | 44,075.33 | 3.66 | 17.66 | 17.66 | 333.11 | 482.41 | 0.4805 | 1.55 | 6.69 | 25,301,370.00 | -1.50 | 2.39 | -1.63 | 3.17 | 85.56 | 85.26 | -3.11 | 6.04 | 6.15 | 2.92 | 0.3398 | 0.00 | 29.84 | 57.56 | -15.26 | -- | 140.50 | -- |
| Katakura Industries Co., Ltd. | 33.88bn | 1.79bn | 60.78bn | 1.06k | 31.97 | 0.8307 | 13.19 | 1.79 | 53.99 | 53.99 | 1,020.07 | 2,077.86 | 0.2494 | 2.72 | 5.33 | 31,989,610.00 | 1.09 | 1.93 | 1.48 | 2.84 | 36.15 | 36.74 | 4.36 | 6.37 | 2.69 | -- | 0.1475 | 21.11 | -5.08 | -4.32 | 72.52 | 23.98 | -16.80 | 9.86 |
| Eiken Chemical Co Ltd | 45.03bn | 6.54bn | 69.01bn | 745.00 | 9.03 | 1.19 | 9.79 | 1.53 | 175.57 | 175.57 | 1,208.08 | 1,329.46 | 0.7061 | 2.79 | 3.38 | 60,436,240.00 | 10.26 | 8.28 | 12.80 | 10.85 | 48.98 | 45.35 | 14.54 | 11.04 | 2.43 | -- | 0.0575 | 31.27 | 11.20 | 5.26 | 23.28 | 16.34 | 20.51 | 15.33 |
| TORII PHARMACEUTICAL CO., LTD. | 48.87bn | 3.99bn | 89.28bn | 560.00 | 21.82 | 0.7365 | 20.10 | 1.83 | 142.09 | 142.09 | 1,739.26 | 4,209.04 | 0.3782 | 2.73 | 2.41 | 87,258,930.00 | 3.09 | 6.82 | 3.37 | 7.85 | 49.14 | 51.06 | 8.17 | 15.53 | 8.03 | -- | 0.00 | 16.78 | 12.68 | -4.84 | -3.46 | 3.51 | -13.22 | 0.00 |
| TOWA PHARMACEUTICAL CO., LTD | 173.86bn | 9.36bn | 102.98bn | 4.08k | 10.71 | 0.7092 | 4.40 | 0.5923 | 186.62 | 186.62 | 3,473.48 | 2,818.59 | 0.5752 | 1.45 | 3.68 | 42,633,890.00 | 3.10 | 5.90 | 4.33 | 7.84 | 39.10 | 44.12 | 5.39 | 10.22 | 0.8056 | -- | 0.518 | 16.48 | 6.92 | 14.28 | 14.01 | 23.34 | -8.50 | 12.47 |
| Shin Nippon Biomedical Laboratories Ltd | 21.17bn | 6.23bn | 104.00bn | 994.00 | 16.69 | 3.69 | 13.45 | 4.91 | 149.68 | 149.68 | 508.61 | 676.88 | 0.4409 | 1.60 | 5.98 | 21,301,740.00 | 13.05 | 5.06 | 18.91 | 7.65 | 53.43 | 45.48 | 29.60 | 14.97 | 0.8221 | -- | 0.373 | 24.13 | 17.46 | 0.5778 | 94.65 | -- | 9.71 | -- |
| KYORIN Holdings, Inc. | 105.53bn | 5.05bn | 107.18bn | 2.22k | 18.81 | 0.7622 | 12.12 | 1.02 | 88.18 | 88.18 | 1,841.56 | 2,176.73 | 0.621 | 1.30 | 3.04 | 47,491,000.00 | 2.97 | 3.33 | 3.66 | 4.03 | 46.13 | 51.06 | 4.79 | 5.46 | 1.87 | -- | 0.1443 | 70.59 | 2.56 | -1.77 | -35.86 | -11.65 | 0.338 | -2.16 |
| Zeria Pharmaceutical Co Ltd | 66.16bn | 5.90bn | 110.59bn | 1.74k | 15.60 | 1.40 | 13.60 | 1.67 | 133.42 | 133.42 | 1,492.07 | 1,489.11 | 0.5030 | 1.53 | 3.55 | 38,087,390.00 | 4.50 | 3.10 | 7.05 | 4.98 | 71.91 | 71.28 | 8.95 | 5.92 | 0.7919 | 4.67 | 0.4396 | 45.87 | 12.84 | -1.70 | 26.03 | 2.25 | -17.52 | 1.81 |
| Kissei Pharmaceutical Co Ltd | 66.93bn | 12.77bn | 127.46bn | 1.83k | 8.88 | 0.5793 | 10.21 | 1.90 | 276.89 | 276.89 | 1,451.39 | 4,246.43 | 0.2848 | 1.68 | 2.50 | 36,614,330.00 | 5.48 | 3.16 | 5.98 | 3.42 | 48.58 | 55.98 | 19.23 | 10.45 | 4.18 | -- | 0.0078 | 34.12 | -5.31 | -1.83 | 144.48 | 10.83 | -5.39 | 4.01 |
| Mochida Pharmaceutical Co Ltd | 109.37bn | 9.58bn | 135.74bn | 1.54k | 13.37 | 0.9755 | 11.10 | 1.24 | 252.77 | 252.77 | 2,899.75 | 3,464.88 | 0.678 | 2.24 | 3.58 | 70,835,500.00 | 5.94 | 5.22 | 7.12 | 6.40 | 53.99 | 51.57 | 8.75 | 7.76 | 3.62 | -- | 0.00 | 40.56 | 6.98 | 2.51 | 23.08 | 4.39 | 21.99 | 3.04 |
Data as of Feb 03 2023. Currency figures normalised to Zeria Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
7.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2022 | 952.05k | 1.79% |
| Nomura Asset Management Co., Ltd.as of 30 Dec 2022 | 835.50k | 1.57% |
| Asset Management One Co., Ltd.as of 15 Sep 2022 | 677.10k | 1.28% |
| Nikko Asset Management Co., Ltd.as of 06 Jan 2023 | 384.60k | 0.72% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2022 | 378.30k | 0.71% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 369.10k | 0.70% |
| BlackRock Fund Advisorsas of 05 Jan 2023 | 220.90k | 0.42% |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 05 Jan 2023 | 169.10k | 0.32% |
| Charles Schwab Investment Management, Inc.as of 05 Jan 2023 | 120.44k | 0.23% |
| Dimensional Fund Advisors LPas of 05 Jan 2023 | 91.01k | 0.17% |
More ▼
Data from 31 Dec 2021 - 31 Dec 2022Source: FactSet Research Systems Inc.
